Glenmark Pharmaceuticals launches Vancomycin Hydrochloride injection in the US – Business Upturn
Glenmark Pharmaceuticals Inc., USA has announced the launch of Vancomycin Hydrochloride for Injection USP in 500 mg/vial and 1 g/vial dosages. This new product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi USA, LLC. The market for Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, achieved annual sales of approximately $37.9 million for…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
